Search Results

B. Braun Medical Inc. (B. Braun), a leader in smart infusion therapy and pain management, announced today the launch of its new Levetiracetam in Sodium Chloride Injection line of products.

Octane Medical Group, through its new venture Octane Biotherapeutics (BioTx), has acquired 100% shares of the global

B. Braun Medical Inc., a leader in smart infusion therapy and pain management, announced a collaboration agreement with Orlando Health, a nationally recognized healthcare provider with award-winning hospitals, to jointly develop innovative solutions to increase access to care for patients and clinicians.

The Board of Directors of B. Braun of America Inc. announced that they have appointed Rob Albert as Chief Executive Officer of B. Braun of America, succeeding Jean-Claude Dubacher who is taking on global management responsibilities, while remaining Chairman of the Board of B. Braun of America.

B. Braun Medical Inc. (B. Braun), a leader in smart infusion therapy and pain management, announced today the launch of its new CARESITE Micro™ Luer Access Device, designed to reduce exposure to harmful chemicals and decrease infection risk, making IV access safer for patients and healthcare providers.

B. Braun Medical Inc., a leader in smart infusion therapy and pain management, announced the launch of its new Heparin Sodium 2,000 units in 0.9% Sodium Chloride Injection, 1,000 mL, the fifth product in its portfolio of Heparin premixed bags.

B. Braun Medical Inc. (B. Braun), a leader in smart infusion therapy and pain management, announced today it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for AQUAbase nX Reverse Osmosis System.

Rockwell Medical, Inc. announced that the Company entered into a three-year co-promotion services agreement with B. Braun Medical Inc., a leader in renal therapies including innovative, high-quality products for hemodialysis.

Meihua International Medical Technologies Co., Ltd., a reputable manufacturer and provider of Class I, II and III disposable medical devices with operating subsidiaries in China, announced that its board of directors has approved and authorized a share repurchase program of up to $3 million of the Company’s outstanding ordinary shares.